Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Saglio, Giuseppe;
2018-01-01

2018
144
5
945
954
link.springer.de/link/service/journals/00432/index.htm
Chronic myeloid leukemia; Clinical trial; Frontline; Nilotinib; Predictors of TFR; Treatment-free remission; Adult; Aged; Aged, 80 and over; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Time Factors; Treatment Outcome; Young Adult; Oncology; Cancer Research
Ross, David M.*; Masszi, Tamas; Gómez Casares, María Teresa; Hellmann, Andrzej; Stentoft, Jesper; Conneally, Eibhlin; Garcia-Gutierrez, Valentin; Gattermann, Norbert; le Coutre, Philipp D.; Martino, Bruno; Saussele, Susanne; Giles, Francis J.; Radich, Jerald P.; Saglio, Giuseppe; Deng, Weiping; Krunic, Nancy; Bédoucha, Véronique; Gopalakrishna, Prashanth; Hochhaus, Andreas
File in questo prodotto:
File Dimensione Formato  
paper2.docx

Accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 244.91 kB
Formato Microsoft Word XML
244.91 kB Microsoft Word XML Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1701792
Citazioni
  • ???jsp.display-item.citation.pmc??? 36
  • Scopus 115
  • ???jsp.display-item.citation.isi??? 104
social impact